Quick Answer
Syndax Pharmaceuticals Inc reported Total Revenue of $172.35 million for the year ending 2025.
- Syndax Pharmaceuticals Inc showed an increase of +627.8% in Total Revenue from 2024 to 2025.
- This data is from Syndax Pharmaceuticals Inc's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $305.0 thousand | Q2 2017: $305.0 thousand | Q3 2017: $305.0 thousand | Q4 2017: $1.19 million | Q1 2018: $379.0 thousand | Q2 2018: $379.0 thousand | Q3 2018: $379.0 thousand | Q4 2018: $380.0 thousand | Q1 2019: $379.0 thousand | Q2 2019: $379.0 thousand | Q3 2019: $379.0 thousand | Q4 2019: $380.0 thousand | Q1 2020: $379.0 thousand | Q2 2020: $379.0 thousand | Q3 2020: $379.0 thousand | Q4 2020: $380.0 thousand | Q1 2021: $379.0 thousand | Q2 2021: $379.0 thousand | Q3 2021: $12.38 million | Q2 2023: $0.00 | Q3 2023: $0.00 | Q1 2024: $0.00 | Q2 2024: $3.50 million | Q3 2024: $12.50 million | Q1 2025: $20.04 million | Q2 2025: $37.96 million | Q3 2025: $45.87 million.
- Over the full 10 years of available data (2016 to 2025), Syndax Pharmaceuticals Inc's Total Revenue has grown by 14,027.2%.
- Historical annual values: Fiscal year 2025: $172.35 million | Fiscal year 2024: $23.68 million | Fiscal year 2023: $0.00 | Fiscal year 2022: $0.00 | Fiscal year 2021: $139.71 million | Fiscal year 2020: $1.52 million | Fiscal year 2019: $1.52 million | Fiscal year 2018: $1.52 million | Fiscal year 2017: $2.11 million | Fiscal year 2016: $1.22 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: